Abstract
Epigenetic gene-regulation abnormalities have been implicated in various neuropsychiatric disorders including schizophrenia and depression, as well as in the regulation of mood and anxiety. In addition, epigenetic mechanisms are involved in the actions of psychiatric drugs. Current anxiolytic drugs have significant shortcomings, and development of new medications is warranted. Two proteins, G9a (also known as EHMT2 or KMT1C) and GLP (G9a-like protein, also known as EHMT1 or KMT1D), which methylate lysine 9 of histone H3 (H3K9), could be promising anxiolytic targets. Postnatal genetic knock-out of G9a reduces anxiety-related behavior, consistent with the reduction of G9a levels by some medications used to treat anxiety (amitriptyline, imipramine and paroxetine). Conversely, there is increased anxiety-like behavior in mice with GLP haplodeficiency. We sought to determine whether two pharmacological inhibitors of G9a/GLP, UNC0642 and A-366, would have similar effects to genetic G9a/GLP insufficiency. We found that G9a/GLP inhibition with either compound reduced anxiety-like behaviors when administered to adult mice, in conjunction with decreased H3K9 methylation in the brain. In contrast, exposure to these compounds from embryonic day 9.5 (E9.5) until birth increased anxiety-like behaviors and decreased social interaction in adulthood, while H3K9 methylation was at normal levels in the brains of the adult mice. These findings reinforce genetic evidence that G9a/GLP has different effects on anxiety-like behavior at different stages of brain development, and suggest that targeting this histone methyltransferase pathway could be useful for developing new anxiolytic drugs. These data also suggest that antidepressant exposure in utero could have negative effects in adulthood, and further investigation of these effects is warranted.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Pelissolo A, Andre C, Chignon JM, Dutoit D, Martin P, Richard-Berthe C, et al. Anxiety disorders in private practice psychiatric out-patients: prevalence, comorbidity and burden (DELTA study). Encephale 2001; 28: 510–9.
Üstün TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ . Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004; 184: 386–92
Onyett SR . The benzodiazepine withdrawal syndrome and its management. J R Coll Gen Pract 1989; 39: 160–3.
Stein DJ, Ipser JC, Seedat S . Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev 2006: CD002795.
Kapczinski F, Lima MS, Souza JS, Schmitt R . Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev 2003: CD003592.
Tsankova N, Renthal W, Kumar A, Nestler EJ . Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 2007; 8: 355–67.
Sun H, Kennedy PJ, Nestler EJ . Epigenetics of the depressed brain: role of histone acetylation and methylation. Neuropsychopharmacology 2013; 38: 124–37.
Klengel T, Mehta D, Anacker C, Rex-Haffner M, Pruessner JC, Pariante CM, et al. Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. Nat Neurosci 2013; 16: 33–41.
McGowan PO, Sasaki A, D'Alessio AC, Dymov S, Labonté B, Szyf M, et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci 2009; 12: 342–8.
Fischer A, Sananbenesi F, Wang X, Dobbin M, Tsai LH . Recovery of learning and memory is associated with chromatin remodelling. Nature 2007; 447: 178–82.
Kilgore M, Miller CA, Fass DM, Hennig KM, Haggarty SJ, Sweatt JD, et al. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 2010; 35: 870–80.
Qing H, He G, Ly PTT, Fox CJ, Staufenbiel M, Cai F, et al. Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J Exp Med 2008; 205: 2781–9.
Kurita M, Holloway T, GarcÃa-Bea A, Kozlenkov A, Friedman AK, Moreno JL, et al. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat Neurosci 2012; 15: 1245–54.
Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ . Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006; 9: 519–25.
Krishnan V, Nestler EJ . The molecular neurobiology of depression. Nature 2008; 455: 894–902.
Covington HE, 3rd, Maze I, LaPlant QC, Vialou VF, Ohnishi YN, Berton O, et al. Antidepressant actions of histone deacetylase inhibitors. J Neurosci 2009; 29: 11451–60.
The UKECTRG . Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003; 361: 799–808.
Tsankova NM, Kumar A, Nestler EJ . Histone modifications at gene promoter regions in rat hippocampus after acute and chronic electroconvulsive seizures. J Neurosci 2004; 24: 5603–10.
Zimmermann N, Zschocke J, Perisic T, Yu S, Holsboer F, Rein T . Antidepressants inhibit DNA methyltransferase 1 through reducing G9a levels. Biochem J 2012; 448: 93–102.
Shankar SR, Bahirvani AG, Rao VK, Bharathy N, Ow JR, Taneja R . G9a, a multipotent regulator of gene expression. Epigenetics 2013; 8: 16–22.
Schaefer A, Sampath SC, Intrator A, Min A, Gertler TS, Surmeier DJ, et al. Control of cognition and adaptive behavior by the GLP/G9a epigenetic suppressor complex. Neuron 2009; 64: 678–91.
Willemsen MH, Vulto-van Silfhout AT, Nillesen WM, Wissink-Lindhout WM, van Bokhoven H, Philip N, et al. Update on Kleefstra syndrome. Mol Syndromol 2012; 2: 202–12.
Liu F, Barsyte-Lovejoy D, Li F, Xiong Y, Korboukh V, Huang XP, et al. Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP. J Med Chem 2013; 56: 8931–42.
Sweis RF, Pliushchev M, Brown PJ, Guo J, Li F, Maag D, et al. Discovery and development of potent and selective inhibitors of histone methyltransferase G9a. ACS Med Chem Lett 2014; 5: 205–9.
Vedadi M, Barsyte-Lovejoy D, Liu F, Rival-Gervier S, Allali-Hassani A, Labrie V, et al. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol 2011; 7: 566–74.
Thase ME . Treatment of anxiety disorders with venlafaxine XR. Expert Rev Neurother 2006; 6: 269–82.
Dhir A, Kulkarni SK . Venlafaxine reverses chronic fatigue-induced behavioral, biochemical and neurochemical alterations in mice. Pharmacol Biochem Behav 2008; 89: 563–71.
Rumbaugh G, Miller CA . Epigenetic changes in the brain: measuring global histone modifications. Methods Mol Biol 2011; 670: 263–74.
Zagni C, Chiacchio U, Rescifina A . Histone methyltransferase inhibitors: novel epigenetic agents for cancer treatment. Curr Med Chem 2013; 20: 167–85.
Balemans MC, Huibers MM, Eikelenboom NW, Kuipers AJ, van Summeren RC, Pijpers MM, et al. Reduced exploration, increased anxiety, and altered social behavior: autistic-like features of euchromatin histone methyltransferase 1 heterozygous knockout mice. Behav Brain Res 2010; 208: 47–55.
Mozzetta C, Pontis J, Fritsch L, Robin P, Portoso M, Proux C, et al. The histone H3 lysine 9 methyltransferases G9a and GLP regulate polycomb repressive complex 2-mediated gene silencing. Mol Cell 2014; 53: 277–89.
Maze I, Covington HE 3rd, Dietz DM, LaPlant Q, Renthal W, Russo SJ, et al. Essential role of the histone methyltransferase G9a in cocaine-induced plasticity. Science 2010; 327: 213–6.
Altieri SC, Yang H, O'Brien HJ, Redwine HM, Senturk D, Hensler JG, et al. Perinatal vs genetic programming of serotonin states associated with anxiety. Neuropsychopharmacology 2015; 40: 1456–70.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary information is available at the website of Acta Pharmacologica Sinica.
Supplementary information
Supplementary Figure S1
Experimental Flow Chart for Chronic G9a/GLP Inhibitor Injection in Adult Mice. (DOC 107 kb)
Supplementary Figure S2
Experimental Flow Chart for In Utero UNC0642 Exposure. (DOC 90 kb)
Supplementary Figure S3
UNC0642 and A-366 treatment did not affect locomotor activities in the elevated zero maze tests. (DOC 139 kb)
Rights and permissions
About this article
Cite this article
Wang, Dy., Kosowan, J., Samsom, J. et al. Inhibition of the G9a/GLP histone methyltransferase complex modulates anxiety-related behavior in mice. Acta Pharmacol Sin 39, 866–874 (2018). https://doi.org/10.1038/aps.2017.190
Received:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/aps.2017.190
Keywords
This article is cited by
-
Inhibition of EHMT1/2 rescues synaptic damage and motor impairment in a PD mouse model
Cellular and Molecular Life Sciences (2024)
-
Dissecting the Relationship Between Neuropsychiatric and Neurodegenerative Disorders
Molecular Neurobiology (2023)
-
Epigenetics meets GPCR: inhibition of histone H3 methyltransferase (G9a) and histamine H3 receptor for Prader–Willi Syndrome
Scientific Reports (2020)
-
Knockdown of the histone di-methyltransferase G9a in nucleus accumbens shell decreases cocaine self-administration, stress-induced reinstatement, and anxiety
Neuropsychopharmacology (2019)
-
Inhibition of G9a by a small molecule inhibitor, UNC0642, induces apoptosis of human bladder cancer cells
Acta Pharmacologica Sinica (2019)
